Study of Azacitidine and Durvalumab in Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
A Study to Determine the Safety and Efficacy for the Combination of Durvalumab and Daratumumab in Relapsed and Refractory Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE2
Abrogation of Chronic Monoclonal Antibody Treatment-induced T-cell Exhaustion With DURVALUMAB in Advanced HER-2 Negative Breast Cancer
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma
- Status
- COMPLETED
- Phase
- PHASE2
Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers
- Status
- COMPLETED
- Phase
- PHASE1
An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)
- Status
- COMPLETED
- Phase
- PHASE2
Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma
- Status
- COMPLETED
- Phase
- PHASE1
Tremelimumab and Durvalumab in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE1
A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
A Study of LY2510924 and Durvalumab in Participants With Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers
- Status
- COMPLETED
- Phase
- PHASE2
A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant
- Status
- TERMINATED
- Phase
- PHASE1